GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » EV-to-EBIT

Tci Gene (ROCO:6879) EV-to-EBIT : 116.25 (As of May. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tci Gene EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tci Gene's Enterprise Value is NT$1,157.7 Mil. Tci Gene's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil. Therefore, Tci Gene's EV-to-EBIT for today is 116.25.

The historical rank and industry rank for Tci Gene's EV-to-EBIT or its related term are showing as below:

ROCO:6879' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.53   Med: 20.72   Max: 148.61
Current: 116.24

During the past 5 years, the highest EV-to-EBIT of Tci Gene was 148.61. The lowest was 11.53. And the median was 20.72.

ROCO:6879's EV-to-EBIT is ranked worse than
94.33% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs ROCO:6879: 116.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tci Gene's Enterprise Value for the quarter that ended in Dec. 2023 was NT$1,340.3 Mil. Tci Gene's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil. Tci Gene's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.74%.


Tci Gene EV-to-EBIT Historical Data

The historical data trend for Tci Gene's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene EV-to-EBIT Chart

Tci Gene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - 24.06 134.58

Tci Gene Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - - 24.06 - 134.58

Competitive Comparison of Tci Gene's EV-to-EBIT

For the Biotechnology subindustry, Tci Gene's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tci Gene's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tci Gene's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tci Gene's EV-to-EBIT falls into.



Tci Gene EV-to-EBIT Calculation

Tci Gene's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1157.684/9.959
=116.25

Tci Gene's current Enterprise Value is NT$1,157.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tci Gene  (ROCO:6879) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tci Gene's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=9.959/1340.31375
=0.74 %

Tci Gene's Enterprise Value for the quarter that ended in Dec. 2023 was NT$1,340.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tci Gene EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tci Gene's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tci Gene (ROCO:6879) Business Description

Traded in Other Exchanges
N/A
Address
No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines